Literature DB >> 7963440

Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?

J E McGowan1.   

Abstract

The relation between antibiotic control and resistance was assessed by review of selected journal articles from 1988 through 1994. Most studies of control or monitoring do not report susceptibility pattern as an outcome measure. Several aspects of bias and confounding prevent more than analysis of temporal association between antibiotic use restriction and resistance pattern. However, in a few institutions there has been an increase in susceptibility to antimicrobials following intensive control or monitoring. Moreover, in a few hospitals, intensive antibiotic control for selected drug-organism pairs was associated with a high prevalence of susceptibility, and the proportion susceptible fell abruptly when control or monitoring was relaxed or removed. These examples, coupled with the recent emergence of new resistant organisms, justify attempts to determine the value of intensive antibiotic control as a preventive practice. Because these studies were performed in single institutions, their power to distinguish associations was poor. Cooperative multicenter studies are needed in which selection and classification biases are addressed prospectively, and in which confounding factors are controlled.

Mesh:

Substances:

Year:  1994        PMID: 7963440     DOI: 10.1086/646954

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  17 in total

Review 1.  Infection and antimicrobial prescribing control in the new millennium: nightmare or nirvana?

Authors:  B Cookson
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

Review 2.  Drug resistance in intensive care units.

Authors:  W C Albrich; M Angstwurm; L Bader; R Gärtner
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 3.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions.

Authors:  Elaine S Walker; Foster Levy; Mahmoud Shorman; Gerard David; Jehad Abdalla; Felix A Sarubbi
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

5.  Antibiotic stewardship in Germany: a cross-sectional questionnaire survey of 355 intensive care units.

Authors:  F Maechler; F Schwab; C Geffers; E Meyer; R Leistner; P Gastmeier
Journal:  Infection       Date:  2013-10-18       Impact factor: 3.553

6.  Association rules and data mining in hospital infection control and public health surveillance.

Authors:  S E Brossette; A P Sprague; J M Hardin; K B Waites; W T Jones; S A Moser
Journal:  J Am Med Inform Assoc       Date:  1998 Jul-Aug       Impact factor: 4.497

7.  Ciprofloxacin or imipenem use correlates with resistance in Pseudomonas aeruginosa.

Authors:  G G Zhanel; L E Nicolle; A S Gin; J Karlowsky; A Kabani; D J Hoban
Journal:  Can J Infect Dis       Date:  1998-11

Review 8.  Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance.

Authors:  A G Carrie; G G Zhanel
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

9.  Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

Authors:  C Peña; M Pujol; C Ardanuy; A Ricart; R Pallares; J Liñares; J Ariza; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

10.  Rapid detection of ampicillin resistance in Escherichia coli by quantitative mass spectrometry.

Authors:  A Grundt; P Findeisen; T Miethke; E Jäger; P Ahmad-Nejad; M Neumaier
Journal:  J Clin Microbiol       Date:  2012-02-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.